公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC | Zhu, Viola W; YEN-TING LIN ; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; CHIA-CHI LIN ; Soo, Ross A | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 45 | 36 | |
2022 | Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study | Simonelli, M; Garralda, E; Eskens, F; Gil-Martin, M; Yen, C-J; Obermannova, R; Chao, Y; Lonardi, S; Melichar, B; Moreno, V; Yu, M-L; Bongiovanni, A; Calvo, E; Rottey, S; Machiels, J-P; Gonzalez-Martin, A; Paz-Ares, L; Chang, C-L; Mason, W; CHIA-CHI LIN ; Reardon, D A; Vieito, M; Santoro, A; Meng, R; Abbadessa, G; Menas, F; Lee, H; Liu, Q; Combeau, C; Ternes, N; Ziti-Ljajic, S; Massard, C | ESMO open | 12 | 8 | |
2019 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial | Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; CHIA-CHI LIN ; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I. | The Lancet Oncology | 234 | 173 | |
2018 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Solomon B.J.; Besse B.; Bauer T.M.; Felip E.; Soo R.A.; Camidge D.R.; Chiari R.; Bearz A.; CHIA-CHI LIN ; Gadgeel S.M.; Riely G.J.; Tan E.H.; Seto T.; James L.P.; Clancy J.S.; Abbattista A.; Martini J.-F.; Chen J.; Peltz G.; Thurm H.; Ignatius Ou S.-H.; Shaw A.T. | The Lancet Oncology | 572 | 458 | |
2018 | Management of Toxicities of Targeted Therapies | CHIH-HSIN YANG ; CHIA-CHI LIN ; CHIA-YU CHU | IASLC Thoracic Oncology | 4 | 0 | |
2011 | Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients | Ng C.M.; Patnaik A.; Beeram M.; CHIA-CHI LIN ; Takimoto C.H. | Cancer Chemotherapy and Pharmacology | 24 | 10 | |
2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
2022 | Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI) | Brose, Marcia S; Smit, Johannes W A; CHIA-CHI LIN ; Tori, Masayuki; Bowles, Daniel W; Worden, Francis; Shen, Daniel Hueng-Yuan; Huang, Shih-Ming; Tsai, Hui-Jen; Alevizaki, Maria; Peeters, Robin P; Takahashi, Shunji; Rumyantsev, Pavel; Guan, Rongjin; Babajanyan, Svetlana; Ozgurdal, Kirhan; Sugitani, Iwao; Pitoia, Fabian; Lamartina, Livia | Thyroid : official journal of the American Thyroid Association | 6 | 5 | |
2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
2019 | Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors | JHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU | Anticancer research | 28 | 29 | |
2017 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations | Wu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG | Expert Review of Respiratory Medicine | 15 | 14 | |
2013 | Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy | Galsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A. | Cancer | 80 | 72 | |
2017 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Oncology Reports | 19 | 19 | |
2007 | Novel targeted therapies for advanced esophageal cancer | CHIA-CHI LIN ; Papadopoulos K.P. | Diseases of the Esophagus | 12 | 12 | |
2020 | Novel trial designs for early phase clinical trials | CHIA-CHI LIN | Phase I Oncology Drug Development | | | |
2019 | Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer | CHIANG, YUN ; Wang, Chung-Chieh; YU-CHIEH TSAI ; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG | Journal of clinical medicine | 8 | 7 | |
2018 | Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy | JHE-CYUAN GUO ; CHIA-CHI LIN ; Ta-Chen Huang ; PEI-MING HUANG ; HUNG-YANG KUO ; Chang C.-H.; CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU ; JANG-MING LEE | Anticancer Research | 12 | 11 | |
2016 | Obesity and outcomes in patients with metastatic urothelial carcinoma | Leiter A.; Doucette J.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Bamias A.; Oh W.K.; Galsky M.D. | Bladder Cancer | 6 | 0 | |
2019 | An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma | El Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K. | Oncologist | 75 | 59 | |
2020 | Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma | Si L.; Zhang X.; Shin S.J.; Fan Y.; CHIA-CHI LIN ; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J. | European Journal of Cancer | 13 | 8 | |